Evotec Acquires Kinaxo Biotech for up to $22M

The acquisition of the chemical proteomics firm allows Evotec it "to take earlier educated decisions on drug efficacy, safety, and response in patients."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.